Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Moshe C Ornstein"'
Autor:
Michael Hurwitz, Mark Stein, Jeffrey Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Meredith M Regan, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Paul J Catalano
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 4 (2024)
Background As part of a partitioned survival analysis, treatment-free survival (TFS) can characterize the overall survival time patients spend between the cessation of immunotherapy and the start of subsequent therapy; both with and without toxicity.
Externí odkaz:
https://doaj.org/article/23ac543db705415f93126b90c7cd9853
Autor:
Alessia Cimadamore, Michael Hurwitz, Mark Stein, Sabina Signoretti, Jeffrey A Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Thomas Denize, Catherine J Wu, David Braun, Paul J Catalano
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background To determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal cell carcinoma (nccRCC) and the efficacy of nivolumab/ipilimumab salvage therapy in patients with tumors unresponsive to
Externí odkaz:
https://doaj.org/article/f31aca68bfec4407896225ae6d30cdbd
Autor:
Tian Zhang, Carl Morrison, Sarabjot Pabla, Jason Zhu, Matthew Zibelman, Shannon McCall, Sean T Glenn, Saby George, Yong Hee Lee, Landon C Brown, Chester Kao, Matthew K Labriola, Rajan T Gupta, Daniel J George, Laura J Tafe, Farshid Dayyani, Kunal Desai, Moshe C Ornstein, Emily Kinsey, Jennifer Tran, Konstantin H Dragnev, Mary K Nesline
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 10 (2022)
Background Immunotherapy combinations including ipilimumab and nivolumab are now the standard of care for untreated metastatic renal cell carcinoma (mRCC). Biomarkers of response are lacking to predict patients who will have a favorable or unfavorabl
Externí odkaz:
https://doaj.org/article/9b968140c98748eb94a5b6265a763e29
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Externí odkaz:
https://doaj.org/article/dae64e52781b44a2a1ebf06a7cb4e9d9
Publikováno v:
Journal of Kidney Cancer and VHL, Vol 4, Iss 2, Pp 10-18 (2017)
Despite significant changes in the therapeutic landscape of renal cell carcinoma, the majority of patients with metastatic disease eventually progress after first-line treatment with vascular endothelial growth factor receptors (VEGFR) tyrosine kinas
Externí odkaz:
https://doaj.org/article/934d097593a048ccb828a4e22b2eb328
Publikováno v:
European Urology Open Science, Vol 44, Iss , Pp 92-93 (2022)
Externí odkaz:
https://doaj.org/article/0e57d7f79d9e49a0b8b217d2b6d3a2ad
Autor:
Haris Zahoor, Pedro C. Barata, Xuefei Jia, Allison Martin, Kimberly D. Allman, Laura S. Wood, Timothy D. Gilligan, Petros Grivas, Moshe C. Ornstein, Jorge A. Garcia, Brian I. Rini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-8 (2018)
Abstract Background Nivolumab is approved for the treatment of refractory metastatic renal cell carcinoma. Patterns and predictors of progressive disease (PD) on nivolumab, and outcomes in such patients are lacking. Methods A retrospective analysis o
Externí odkaz:
https://doaj.org/article/f6ec2bd029234b5785f346286c3599fb
Autor:
Iris Y. Sheng, Shilpa Gupta, Chandana A. Reddy, Dana Angelini, Pauline Funchain, Tamara A. Sussman, Joseph Sleiman, Moshe C. Ornstein, Keith McCrae, Alok A. Khorana
Publikováno v:
Targeted Oncology. 17:563-569
Autor:
Moshe C. Ornstein, Laura S. Wood
Publikováno v:
Advances in Therapy.
Autor:
Petros Grivas, Omar Y. Mian, Mohamed E. Abazeed, Brian I. Rini, Moshe C. Ornstein, Timothy Gilligan, Afshin Dowlati, Georges-Pascal Haber, Byron H. Lee, Amr F. Fergany, Andrew J. Stephenson, Ming Hu, Summya Rashid, Aysegul Balyimez, Laura R. Saunders, Evan Bishop, Kumiko Isse, Jesse K. McKenney, Cristina Magi-Galluzzi, Paul Elson, Jordan Reynolds, Jorge A. Garcia, Vadim S. Koshkin
Purpose:Transcriptomic profiling can shed light on the biology of small-cell bladder cancer (SCBC), nominating biomarkers, and novel therapeutic targets.Experimental Design:Sixty-three patients with SCBC had small-cell histology confirmed and quantif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40a9cf231a44f20c7c8a2ca6aef6f255
https://doi.org/10.1158/1078-0432.c.6528731.v1
https://doi.org/10.1158/1078-0432.c.6528731.v1